MXPA05012101A - Bolsillo de union al inhibidor de polimerasa ns5b del virus de la hepatitis c. - Google Patents

Bolsillo de union al inhibidor de polimerasa ns5b del virus de la hepatitis c.

Info

Publication number
MXPA05012101A
MXPA05012101A MXPA05012101A MXPA05012101A MXPA05012101A MX PA05012101 A MXPA05012101 A MX PA05012101A MX PA05012101 A MXPA05012101 A MX PA05012101A MX PA05012101 A MXPA05012101 A MX PA05012101A MX PA05012101 A MXPA05012101 A MX PA05012101A
Authority
MX
Mexico
Prior art keywords
binding pocket
hepatitis
ns5b polymerase
polymerase inhibitor
hcv ns5b
Prior art date
Application number
MXPA05012101A
Other languages
English (en)
Inventor
Steven Laplante
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MXPA05012101A publication Critical patent/MXPA05012101A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/18Togaviridae; Flaviviridae
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)
    • C12N9/127RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2299/00Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La polimerasa NS5B del HCV, cuando se compleja con ciertos inhibidores, adopta una conformacion en la que la region del bucle de dedo definida por los residuos aminoacidos 18 a 35 esta desplazada para exponer un bolsillo de union generalmente definido por los residuos de aminoacidos 392, 393, 395, 396, 399, 424, 425, 428, 429, 492, 493, 494, 495, 496, 500 y 503. Este bolsillo de union recientemente expuesto define una nueva diana en la busqueda de entidades quimicas adicionales que son capaces de unirse a NS5B del HCV y de modular, o preferiblemente inhibir, la actividad de polimerasa NS5B del HCV.
MXPA05012101A 2003-05-09 2004-05-05 Bolsillo de union al inhibidor de polimerasa ns5b del virus de la hepatitis c. MXPA05012101A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46960403P 2003-05-09 2003-05-09
PCT/CA2004/000676 WO2004099241A1 (en) 2003-05-09 2004-05-05 Hepatitis c virus ns5b polymerase inhibitor binding pocket

Publications (1)

Publication Number Publication Date
MXPA05012101A true MXPA05012101A (es) 2006-02-08

Family

ID=33435247

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012101A MXPA05012101A (es) 2003-05-09 2004-05-05 Bolsillo de union al inhibidor de polimerasa ns5b del virus de la hepatitis c.

Country Status (12)

Country Link
US (1) US7386398B2 (es)
EP (1) EP1625154B1 (es)
JP (1) JP4584909B2 (es)
KR (1) KR101164070B1 (es)
CN (1) CN100457776C (es)
AU (1) AU2004235848B2 (es)
CA (1) CA2522574C (es)
DK (1) DK1625154T3 (es)
ES (1) ES2456702T3 (es)
IL (1) IL171800A (es)
MX (1) MXPA05012101A (es)
WO (1) WO2004099241A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012288A1 (en) 2003-08-01 2005-02-10 Genelabs Technologies, Inc Bicyclic imidazol derivatives against flaviviridae
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8535334B2 (en) * 2007-04-17 2013-09-17 Lazarus Effect, Inc. Complex wire formed devices
US20100286131A1 (en) * 2007-08-03 2010-11-11 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CA2693997C (en) 2007-08-03 2013-01-15 Pierre L. Beaulieu Viral polymerase inhibitors
WO2009033183A2 (en) * 2007-09-08 2009-03-12 University Of Florida Research Foundation Compounds and methods for treatment of hcv and conditions associated with cd81 binding
BRPI0703586B1 (pt) * 2007-10-19 2018-02-06 Braskem S.A Catalisador metaloceno suportado, e, copolímeros de etileno com alfa-olefinas de alto e ultra alto peso molecular
US8476257B2 (en) 2007-12-19 2013-07-02 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
BRPI0922364A2 (pt) * 2008-12-03 2017-08-29 Presidio Pharmaceuticals Inc Composto, composição farmacêutica e uso de um composto
WO2010081149A1 (en) * 2009-01-12 2010-07-15 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
EP2398474A4 (en) * 2009-02-23 2012-12-05 Presidio Pharmaceuticals Inc HCV NS5A SHEMMER
BRPI1009034A2 (pt) * 2009-06-30 2019-09-24 Siga Tech Inc composição farmacêutica e método para o tratamento ou profilaxia de uma infecção viral ou doença associada a mesma
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
US20110053892A1 (en) * 2009-08-31 2011-03-03 Martin Leivers Imidazo[4,5-d]Pyridazine Compounds For Treating Viral Infections
US20110065782A1 (en) * 2009-09-15 2011-03-17 Malliavin Therese Methods of identifying compounds that inhibit the activation of a biomolecule and methods of treatment using the compounds
TW201138786A (en) * 2010-02-19 2011-11-16 Glaxo Group Ltd Therapeutic compounds
US20130296311A1 (en) * 2010-05-28 2013-11-07 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2012040389A2 (en) 2010-09-22 2012-03-29 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
WO2012050918A2 (en) 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Tricyclic fused ring inhibitors of hepatitis c
BR112013009789A2 (pt) 2010-10-26 2016-07-19 Presidio Pharmaceuticals Inc inibidores do vírus da hepatite c
WO2012059413A1 (en) * 2010-11-02 2012-05-10 Probiodrug Ag Crystal structure of isoglutaminyl cyclase
SI2640719T1 (sl) 2010-11-17 2017-07-31 Gilead Pharmasset Llc Antivirusne spojine
WO2012083059A1 (en) * 2010-12-15 2012-06-21 Abbott Laboratories Anti-viral compounds
JP6041877B2 (ja) * 2011-08-12 2016-12-14 サザン リサーチ インスティテュート キナゾリノン類似体及び特定のウイルス感染症の治療又は予防へのキナゾリノン類似体の使用
PL2907816T3 (pl) 2011-11-16 2019-03-29 Gilead Pharmasset Llc Skondensowane imidazolyloimidazole jako związki przeciwwirusowe
CN108409820A (zh) 2011-12-20 2018-08-17 里博科学有限责任公司 作为hcv rna复制抑制剂的4′-叠氮基,3′-氟取代的核苷衍生物
US20150087045A1 (en) * 2012-01-13 2015-03-26 Gilead Pharmassset Llc Crystal structure of hcv polymerase complexes and methods of use
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
US9167288B2 (en) 2013-03-15 2015-10-20 Universal Electronics Inc. System and method for optimizing memory usage in a universal controlling device
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
US9895442B2 (en) * 2013-05-16 2018-02-20 Riboscience Llc 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
EP2996696A4 (en) 2013-05-16 2016-12-21 Riboscience Llc 4'-AZIDO, 3'-DEOXY-3'-FLUOR-SUBSTITUTED NUCLEOSIDE DERIVATIVES
CN105579046A (zh) 2013-08-26 2016-05-11 英安塔制药有限公司 用于预防或治疗丙型肝炎的环孢菌素类似物
PL3650014T3 (pl) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Preparat złożony dwóch związków przeciwwirusowych
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
WO2016033164A1 (en) 2014-08-26 2016-03-03 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
WO2016073480A1 (en) 2014-11-03 2016-05-12 Enanta Pharmaceuticals, Inc. Novel cyclosporin analogues for preventing or treating hepatitis c infection
US9718851B2 (en) 2014-11-06 2017-08-01 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
CN104530189B (zh) * 2014-12-16 2017-11-14 郑州大学第一附属医院 丙型肝炎病毒ns5b rna聚合酶抑制多肽序列及其用途
CN111194217B (zh) 2017-09-21 2024-01-12 里伯赛恩斯有限责任公司 作为hcv rna复制抑制剂的4’-氟-2’-甲基取代的核苷衍生物
WO2023172635A1 (en) * 2022-03-08 2023-09-14 Emory University Predictive model for variants associated with drug resistance and theranostic applications thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5528559A (en) * 1995-06-23 1996-06-18 Motorola, Inc. Multiple display timepiece
WO1999057253A2 (en) * 1998-05-04 1999-11-11 Vertex Pharmaceuticals Incorporated Crystallizable jnk complexes
US6434489B1 (en) * 2000-04-03 2002-08-13 Schering Corporation Compositions of hepatitis C virus NS5B polymerase and methods for crystallizing same
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP1256628A3 (en) * 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
JP4558314B2 (ja) * 2001-07-20 2010-10-06 ベーリンガー インゲルハイム (カナダ) リミテッド ウイルスポリメラーゼインヒビター
CA2459890A1 (en) * 2001-09-06 2003-03-20 Biogen Idec Ma Inc. Crystal structure of baff, and use thereof in drug design
US7223785B2 (en) * 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors

Also Published As

Publication number Publication date
US7386398B2 (en) 2008-06-10
CN1820022A (zh) 2006-08-16
JP4584909B2 (ja) 2010-11-24
CA2522574A1 (en) 2004-11-18
CA2522574C (en) 2015-07-07
AU2004235848A1 (en) 2004-11-18
IL171800A (en) 2013-06-27
KR101164070B1 (ko) 2012-07-12
EP1625154A1 (en) 2006-02-15
WO2004099241A1 (en) 2004-11-18
CN100457776C (zh) 2009-02-04
US20050003348A1 (en) 2005-01-06
KR20060011861A (ko) 2006-02-03
EP1625154B1 (en) 2014-01-08
ES2456702T3 (es) 2014-04-23
DK1625154T3 (da) 2014-02-24
JP2007534292A (ja) 2007-11-29
AU2004235848B2 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
MXPA05012101A (es) Bolsillo de union al inhibidor de polimerasa ns5b del virus de la hepatitis c.
WO2004014852A3 (en) Iminothiazolidinones as inhibitors of hcv replication
TW200518746A (en) Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
EP1771454A4 (en) PEPTIDE ANALOGUE AS HEPATITIS C HEMMER
TW200615275A (en) Hepatitis C inhibitor dipeptide analogs
UA86962C2 (en) Viral polymerase inhibitors
MY140680A (en) Hepatitis c virus inhibitors
ATE474827T1 (de) Hcv-replikationshemmer
WO2006086381A3 (en) Hepatitis c virus inhibitors
TW200508220A (en) Hepatitis C inhibitor compounds
DE60319820D1 (de) Pyrazoloä1,5-aüpyrimidin-verbindungen als antivirale agentien
DE60111509D1 (de) Inhibitoren von serin proteasen, speziell der hepatitis-c-virus ns3-protease
ATE542826T1 (de) Inhibitoren des hepatitis-c-virus
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
NO20044897L (no) Hepatitt C virus inhibitorer
IS7532A (is) Heterósýklískir súlfónamíð lifrarbólgu C-veirutálmar
MX2007000007A (es) Inhibidores de polimerasa viral.
RS67004A (en) Macrocyclic peptides active against the hepatitis c virus
ATE486889T1 (de) Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
WO2007027248A3 (en) 3', 5' - cyclic nucleoside analogues for treatment of hcv
EA200900676A1 (ru) Ингибиторы вируса гепатита с
MX2008001402A (es) Inhibidores macrociclicos del virus de la hepatitis c.
SG155967A1 (en) Hcv ns3-ns4a protease inhibition
WO2007092645A3 (en) Novel hcv inhibitor combinations and methods
WO2005000308A3 (en) Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c

Legal Events

Date Code Title Description
FG Grant or registration